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The Pediatric Allergy and Immunology (PAI) Unit 
of Ain Shams University, founded in 1988 by 
Professor Yehia El-Gamal and currently headed by 
Professor Shereen Reda, is a tertiary referral center 
for pediatric allergy, primary immunodeficiency, 
and rheumatology patients in Egypt. It serves more 
than 1300 patients with different immunological 
disorders, with an outpatient and inpatient sections 
and investigational laboratory. With the widespread 
of the SARS-CoV-2 and its declaration as a 
"pandemic", and owing to the heterogeneity of the 
different disorders managed and followed up in the 
unit, several measures have been taken in order to 
provide the necessary services for the patients. This 
service should maintain a rational balance between 
the need to mitigate the virus spread and to provide 
the optimum care for those who get infected, when 
in the meantime keep their original disease 
morbidity and mortality to the minimum. These 
measures were taken by the members of the PAI 
unit with the help of the head management team of 
Children’s Hospital, Ain Shams University and 
were subjected to continuous modification based on 
the evolving situation, emerging information, 
problems faced and the availability of human and 
medical resources.  
 
Measures taken in the PAI unit-outpatient 
clinics 
Since the start of the pandemic and realizing the 
critical situation, the clinics were shifted from 
routine follow up visits of patients to emergency 
management of problematic cases. Messages were 
sent on mobile phones of parents whose contact 
details were available, for reassurance, advice about 
the necessary protective measures, and for 
emphasizing the importance of adherence to 
treatment in order to minimize disease exacerbation  
 
 
and the need for hospitalization. Regular follow up 
visits of patients were spaced, and medications 
were prescribed in sufficient amounts to cover 
longer duration than usual for patients in remission. 
Patients were encouraged to report to their 
physicians, via phone calls, any emerging 
symptoms and were instructed to seek medical help 
in emergency situations or based on physician’s 
advice. In the Clinic, personal protective measures 
were provided by the hospital for the physicians, 
and patients were instructed to follow the general 
precautions of hand washing, mask wearing and 
social distancing all through the clinic visit. Aerosol 
generating procedures, such as inhalation therapy 
via nebulizers were withheld from the clinic and 
were only prescribed for home management. Skin 
prick tests and pulmonary function tests were 
withheld as well, except for limited selected cases 
after weighing the risk versus benefit, while routine 
dates were cancelled.1,2 
A triaging system has been applied as a 
mandatory step for patients for the detection of 
suspected cases (those presenting with fever, chest 
symptoms, gastrointestinal symptoms, and 
anosmia/ageusia) before being allowed to the PAI 
clinic. COVID-19 suspected cases were 
immediately referred to a transit ward to undergo a 
swab test for SARS-CoV-2 by PCR. However, the 
differentiation between infection and 
immunological disease activity, especially among 
patients with rheumatologic and autoinflammatory 
disorders, was a real challenge, as the 
aforementioned symptoms could be part of the 
disease exacerbation, a situation that necessitated 
extensive laboratory workup and repeated SARS-
CoV-2 swabs to exclude SARS-CoV-2 infection 
before taking decisions to start or modify the 
immunosuppressive treatment. We adopted 
judicious use of immunosuppressive treatment 
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especially n-methyl prednisolone pulsed therapy 
and cyclophosphamide with restricted use of 
rituximab. Patients on intravenous 
immunoglobulins were maintained on regular 
dosing as possible regardless their insurance 
coverage, to minimize the risk of infections and the 
need of hospitalization.  
 
Measures taken in the PAI unit-inpatient section 
As most of the PAI patients are considered 
immunocompromised, whether having a primary 
immunodeficiency disorder or developed secondary 
immunosuppression by medications, the admission 
of patients to the PAI inpatients ward was only 
done after the exclusion of SARS-CoV-2 infection 
(by swabs for PCR and antibody testing). Patients 
were thus admitted to a transit ward until 
investigated before being admitted to the PAI 
inpatients ward. Visitors to the inpatients were 
minimized. All physicians, nurses, workers, and 
caregivers were instructed to adopt protective 
measures during hospital attendance. Disinfection 
measures were continuously applied.  In case of 
development of any symptoms or signs suggestive 
of SARS-CoV-2 infection, swabs were repeated, 
together with laboratory and radiological 
evaluation, guided by the hospital protocol for 
SARS-CoV-2 diagnosis and management 
algorithm. In case SARS-CoV-2 infection is proven 
in an admitted case, all contacting physicians, 
nurses and workers were tested for infection, and 
the case was immediately transferred to the 
COVID-19 isolation ward in the same hospital 
including those who required intensive care unit 
admission. 
 
Measures taken for the PAI unit-working staff 
The PAI working staff members were classified 
into two alternating teams, to allow safe distancing 
and minimize exposure.  Whenever a staff member 
develops symptoms suggestive of COVID-19, 
he/she undergoes a PCR testing for COVID-19 and 
is sent home for isolation. In that case, the 
alternating physician takes over. Meetings are 
carried out regularly for the discussion of the 
diagnosis and management of complicated cases 
but through online platforms. Consultants are 
available 3 days per week, and specialists 4 days a 
week for the assessment of outpatient and inpatient 
cases. Several webinars are being held for 
discussing the emerging information about COVID-
19, its different presentations, diagnosis, and 
management. Emerging scientific information is 
shared among all the PAI unit members and the 
whole team is continuously updated with the 
COVID-19 presentations observed in our allergic, 
rheumatologic and immunodeficiency patients. All 
data relevant to COVID-19 in our patients are 
compiled and are prepared for publishing with the 
aim of spreading information in due time. 
 
Challenges faced by the PAI unit during the 
SARS-CoV-2 pandemic 
Management of work in the PAI Unit during the 
SARS-CoV-2 pandemic is not without challenges. 
At the outset, the lack of sufficient information and 
the limited sensitivity of the available rapid viral 
testing were among the early challenges. Many 
times, the clinical presentations of COVID-19, and 
the laboratory findings mimicked those of 
rheumatic disease activity. Patients with rheumatic 
disorders tended to stop their immunosuppressive 
treatment without medical consultation for fear of 
contagion. This predisposed them to disease flare. 
Intravenous immunoglobulins and certain anti-
rheumatic drugs (such as hydroxychloroquine and 
tocilizumab) are consumed in the pandemic, which 
markedly affects their availability for our patients.3 
Infections among the healthcare workers was 
another challenging problem. 
In summary, our PAI Unit has taken several 
measures with the help of the Children’s Hospital 
management team for providing the optimum care 
of patients and minimizing losses in patients and 
health care workers. Still, the situation is 
challenging, and more efforts are needed to provide 
continuing support of the patients and integrating 
the clinical work with research activity. On the 
horizon, multicenter analysis of COVID-19 
patients’ data will provide a more comprehensive 
view and might provide accurate information that 
would allow better decision making. The PAI unit 
is thanking its entire working staff including 
professors, consultants, specialists, residents, 
nurses, and infection control team for their 
courageous and continuous efforts in facing of the 
pandemic. The unit is also grateful to the pediatric 
dialysis and intensive care units for their extreme 
support throughout this challenging time. 
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